Daniel L. Flynn

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Sheng-Bin Peng, James R. Henry, Michael D. Kaufman et al. · Cancer Cell · 2015 · 305 citations · Full text

Ly3009120 Leads, Raf Isoforms, Medicine +8

A mild two-step method for the hydrolysis of lactams and secondary amides

Daniel L. Flynn, Robert E. Zelle, Paul A. Grieco · The Journal of Organic Chemistry · 1983 · 272 citations

Bioorganic Chemistry, Engineering, Chemical Analysis +17

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu et al. · Cancer Cell · 2019 · 270 citations

Pdgfra Variants, Oncogenic Agent, Medicine +9

Chemical Library Purification Strategies Based on Principles of Complementary Molecular Reactivity and Molecular Recognition

Daniel L. Flynn, J. Z. CRICH, Rajesh Devraj et al. · Journal of the American Chemical Society · 1997 · 211 citations

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

Wayne W. Chan, Scott Wise, Michael D. Kaufman et al. · Cancer Cell · 2011 · 204 citations · Full text

Switch-control Inhibitor Dcc-2036, Signal Transduction, Signaling Pathway +9